10 suspended. 10 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Suspended 10 |
| Phase 2 | 1 | Suspended 1 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 24 | 2024-11-06 | 2026-06-05 |
| Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 33 | 2024-05-24 | 2026-10-15 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies anti-TRBC1 CAR-T cell therapy - Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Suspended | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 9 | 2021-03-31 | 2023-11-29 |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome Fludarabine, Laboratory Biomarker Analysis, Melphalan - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission | Phase 1 | Suspended | City of Hope Medical Center | 36 | 2018-07-06 | 2026-09-28 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy - Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Suspended | University of Chicago | 30 | 2014-12-05 | 2026-03-30 |
| Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) P1446A-05 - Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Suspended | Piramal Enterprises Limited | 36 | 2014-06-01 | 2014-09-03 |
| BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy - Leukemia, Lymphoma | Phase 1 | Suspended | MedImmune LLC | 95 | 2004-01-01 | 2007-12-28 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Myeloid, Acute (5) · Immunoblastic Lymphadenopathy (3) · Myelodysplastic Syndromes (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Burkitt Lymphoma (1) · Colorectal Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Enteropathy-Associated T-Cell Lymphoma (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Leukemia (9) · Leukemia, Myeloid (5) · Lymphoma, Non-Hodgkin (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bone Marrow Diseases (3)
Melphalan (3) · fludarabine (3) · Biopsy (2) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Tacrolimus (2) · fludarabine phosphate (2) · Antibodies, Monoclonal (1) · Cetuximab (1) · IL32 protein, human (1) · Interleukin-2 (1) · Leukapheresis (1) · Lymphatic Irradiation (1) · Mycophenolic Acid (1)
City of Hope Medical Center (3) · David Wald (1) · MedImmune LLC (1) · Piramal Enterprises Limited (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · SymBio Pharmaceuticals (1) · University of Chicago (1) · Washington University School of Medicine (1)
United States (8) · China (2) · Japan (1) · Singapore (1)
Alan S. Wayne, MD (1) · Amandeep Salhotra (1) · Benjamin Tomlinson, MD (1) · Dr Alexey V Danilov, MD, PhD (1) · Dr Jennifer R Brown, MD, PhD (1) · Geoffrey Uy, M.D. (1) · Hongtao Liu (1) · Ibrahim Aldoss (1) · Monzr Al Malki (1)
P30CA033572 (2), P30CA014599 (1)